NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 33.5% in January

NextCure, Inc. (NASDAQ:NXTC) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 55,000 shares, an increase of 33.5% from the January 15th total of 41,200 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 158,000 shares, the short-interest ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their target price on shares of NextCure from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Monday, November 11th.

NextCure Trading Up 4.5 %

NXTC traded up $0.03 during trading on Friday, hitting $0.76. 33,479 shares of the company traded hands, compared to its average volume of 75,547. The company has a market cap of $21.21 million, a PE ratio of -0.36 and a beta of 0.66. The stock’s 50-day simple moving average is $0.85 and its two-hundred day simple moving average is $1.20. NextCure has a 1 year low of $0.66 and a 1 year high of $2.57.

Hedge Funds Weigh In On NextCure

Several institutional investors have recently bought and sold shares of NXTC. Geode Capital Management LLC lifted its position in NextCure by 14.2% during the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock valued at $307,000 after purchasing an additional 27,812 shares during the last quarter. Peapod Lane Capital LLC bought a new position in NextCure during the fourth quarter valued at $311,000. Finally, Renaissance Technologies LLC lifted its position in NextCure by 27.9% during the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after purchasing an additional 113,300 shares during the last quarter. 42.65% of the stock is owned by hedge funds and other institutional investors.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.